Please login to the form below

Not currently logged in
Email:
Password:

Drug cure for breast cancer

Delegates at the European Breast Cancer Conference in Germany have seen new data revealing that Herceptin could prove an effective breast cancer cure
Delegates at the European Breast Cancer Conference (EBCC) in Germany have seen new data revealing that Herceptin could prove an effective breast cancer cure.

Herceptin (trastuzumab) has been developed for use in conjunction with chemotherapy prior to breast cancer surgery (neoadjuvant therapy). Results from the GeparQuatrro study, a randomised phase III trial, show that 45.5 per cent of female patients with HER2-positive breast cancer experienced complete tumour eradication.

Dr von Minckwitz of the University Women's Hospital in Frankfurt and managing director of German Breast Group, said: "Herceptin offers real hope for women with early breast cancer."

"Herceptin delivered on its promise of high tumour eradication when given to women with this aggressive form of breast cancer before their surgery," added Dr Minckwitz.

Over 1 million people are diagnosed with breast cancer worldwide with the disease claiming the lives of 400,000 patients annually.

According to Dr Untch, Helios Clinics in Berlin, "Herceptin makes women with this aggressive type of breast cancer feel more confident about their future".

HER2-positive breast cancer occurs in 20 to 30 per cent of all diagnosed cases. It is fast growing and is high likelihood of recurrence in patients. Herceptin is designed to target and block the function of HER2, a protein that has cancer causing potential.

18th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics